Department of Immunoregulation & Immunodiagnostics, Chittaranjan National Cancer Institute, 5 Main Road, Royapuram, Kolkata, India.
Indian J Med Res. 2012 Jul;136(1):54-9.
BACKGROUND & OBJECTIVES: Interferon alpha 2b (IFNα2b) has been reported to regulate several immune functions efficiently to enhance the cytotoxic activity of NK and T cells towards various forms of tumours. The objective of the present study was to evaluate the efficacy of IFNα2b in overcoming disease induced and/or treatment associated imunosuppression of tongue squamous cell carcinoma (TSCC) patients undergoing chemotherapy for better clinical outcome.
Seven TSCC patients under cisplatin + 5-fluorouracil chemotherapy in combination with IFNα2b were assessed for various immunohaematological parameters before treatment, after chemotherapy and after IFNα2b therapy.
Deterioration of the haematological and immune responses was detected in immunosuppressed TSCC patients after chemotherapy. IFNα2b treatment led to a recovery in these parameters in most of the patients. Greater number of T/NK cells and enhanced secretion of type 1 cytokines were also noted. Haematological complications were reduced after completion of the therapy. Immune- and haematostimulation were also observed in patients with partial response. No positive clinical response was detected in one patient.
INTERPRETATION & CONCLUSIONS: IFNα2b appears to be an effective immunostimulator having clinical impact to combat the immunosuppression in TSCC patients. Successful immunostimulation by IFNα2b may help TSCC patients in clinical improvement. The findings of this preliminary study need to be confirmed on a large number of patients with TSCC.
干扰素 α2b（IFNα2b）已被报道能够有效地调节多种免疫功能，增强 NK 和 T 细胞对各种形式肿瘤的细胞毒性活性。本研究旨在评估 IFNα2b 克服舌鳞状细胞癌（TSCC）患者在接受化疗时发生的疾病诱导和/或治疗相关免疫抑制的疗效，以期获得更好的临床结果。
对 7 例接受顺铂+5-氟尿嘧啶化疗联合 IFNα2b 治疗的 TSCC 患者，在治疗前、化疗后和 IFNα2b 治疗后评估了各种免疫血液学参数。
化疗后免疫抑制的 TSCC 患者的血液学和免疫反应恶化。IFNα2b 治疗使大多数患者的这些参数得到恢复。还观察到 T/NK 细胞数量增加和 1 型细胞因子分泌增强。治疗完成后，血液学并发症减少。部分缓解患者也观察到免疫和血液刺激作用。一名患者未检测到阳性临床反应。
IFNα2b 似乎是一种有效的免疫刺激剂，具有临床影响，可对抗 TSCC 患者的免疫抑制。IFNα2b 的成功免疫刺激可能有助于 TSCC 患者的临床改善。这项初步研究的结果需要在大量 TSCC 患者中得到证实。
